These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 22922005)
1. Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. Bigarella CL; Ferro KP; Barcellos KS; Martins-de-Souza D; Traina F; Novello JC; Saad ST; Archangelo LF FEBS Lett; 2012 Sep; 586(19):3522-8. PubMed ID: 22922005 [TBL] [Abstract][Full Text] [Related]
2. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Matic I; Schimmel J; Hendriks IA; van Santen MA; van de Rijke F; van Dam H; Gnad F; Mann M; Vertegaal AC Mol Cell; 2010 Aug; 39(4):641-52. PubMed ID: 20797634 [TBL] [Abstract][Full Text] [Related]
3. The putative nuclear localization signal of the human RAD52 protein is a potential sumoylation site. Saito K; Kagawa W; Suzuki T; Suzuki H; Yokoyama S; Saitoh H; Tashiro S; Dohmae N; Kurumizaka H J Biochem; 2010 Jun; 147(6):833-42. PubMed ID: 20190268 [TBL] [Abstract][Full Text] [Related]
4. Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma. Liu J; Sha M; Wang Q; Ma Y; Geng X; Gao Y; Feng L; Shen Y; Shen Y BMC Cancer; 2015 Oct; 15():675. PubMed ID: 26458400 [TBL] [Abstract][Full Text] [Related]
5. SUMO assay with peptide arrays on solid support: insights into SUMO target sites. Schwamborn K; Knipscheer P; van Dijk E; van Dijk WJ; Sixma TK; Meloen RH; Langedijk JP J Biochem; 2008 Jul; 144(1):39-49. PubMed ID: 18344540 [TBL] [Abstract][Full Text] [Related]
6. SUMOylation of HSP27 by small ubiquitin-like modifier 2/3 promotes proliferation and invasion of hepatocellular carcinoma cells. Ge H; Du J; Xu J; Meng X; Tian J; Yang J; Liang H Cancer Biol Ther; 2017 Aug; 18(8):552-559. PubMed ID: 28665748 [TBL] [Abstract][Full Text] [Related]
7. SUMO2 and SUMO3 transcription is differentially regulated by oxidative stress in an Sp1-dependent manner. Sang J; Yang K; Sun Y; Han Y; Cang H; Chen Y; Shi G; Wang K; Zhou J; Wang X; Yi J Biochem J; 2011 Apr; 435(2):489-98. PubMed ID: 21291420 [TBL] [Abstract][Full Text] [Related]
9. SUMO2/3 modification of activating transcription factor 5 (ATF5) controls its dynamic translocation at the centrosome. Yuan Y; Gaither K; Kim E; Liu E; Hu M; Lengel K; Qian D; Xu Y; Wang B; Knipprath H; Liu DX J Biol Chem; 2018 Feb; 293(8):2939-2948. PubMed ID: 29326161 [TBL] [Abstract][Full Text] [Related]
10. The transcriptional repression activity of KyoT2 on the Notch/RBP-J pathway is regulated by PIAS1-catalyzed SUMOylation. Wang J; Qin H; Liang J; Zhu Y; Liang L; Zheng M; Han H J Mol Biol; 2007 Jun; 370(1):27-38. PubMed ID: 17509614 [TBL] [Abstract][Full Text] [Related]
14. FRET-based in vitro assays for the analysis of SUMO protease activities. Tatham MH; Hay RT Methods Mol Biol; 2009; 497():253-68. PubMed ID: 19107423 [TBL] [Abstract][Full Text] [Related]
15. A novel method for high accuracy sumoylation site prediction from protein sequences. Xu J; He Y; Qiang B; Yuan J; Peng X; Pan XM BMC Bioinformatics; 2008 Jan; 9():8. PubMed ID: 18179724 [TBL] [Abstract][Full Text] [Related]
16. Human SUMO fusion systems enhance protein expression and solubility. Wang Z; Li H; Guan W; Ling H; Wang Z; Mu T; Shuler FD; Fang X Protein Expr Purif; 2010 Oct; 73(2):203-8. PubMed ID: 20457256 [TBL] [Abstract][Full Text] [Related]